Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

Table 4 American College of Rheumatology core outcomes after 6 months

	Etanercept plus methotrexate	Etanercept only	P value
SJC	3.95 ± 0.65	4.27 ± 0.84	Not significant
TJC	4.85 ± 0.87	4.62 ± 0.77	Not significant
HAQ	1.30 ± 0.1	1.56 ± 0.1	Not significant
Patient global	30.5 ± 4.6	36.4 ± 5.5	< 0.05
Patient pain	29.5 ± 3.5	36.8 ± 4.3	Not significant
Physician global	1.55 ± 0.1	1.17 ± 0.1	< 0.02
ESR	19.4 ± 2.35	25.0 ± 3.31	Not significant

Values presented as mean ± standard error of the mean. Comparisons are by unpaired Student t test. ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire disability index; patient global, patient assessment of global health by 100 mm visual analogue scale; patient pain, patient assessment of pain by 100 mm visual analogue scale; physician global, physician's assessment of global disease activity by five-point scale (0–4); SJC, swollen joint count (based on 28 joints); TJC, tender joint count (based on 28 joints).

ISSN: 1478-6362